
MTVA Stock Forecast & Price Target
MTVA Analyst Ratings
Bulls say
MetaVia is expected to deliver data in 4Q26 on their DA-1726 program, with focus on successful titration and increased weight loss. Additionally, looking for continued progress on vanoglipel and potential FDA guidance on their MASH program will be key. With $13.7M in cash and runway into 4Q26, their financials appear stable, but execution will remain a crucial factor in their success.
Bears say
MetaVia is facing significant questions regarding the outcome of their 4Q26 topline Phase 1 data readout for their novel GPR119 agonist, Vanoglipel. The success of the 64 mg dose in producing a meaningful dose-response benefit over 48 mg, along with tolerability profiles and potential differentiation in the increasingly crowded obesity/MASH market, will likely be the key determining factors for investors considering the efficacy of this drug. Ahead of the data readout, comparing the data against other drugs in the market and gathering insights from KOLs will be crucial in assessing the potential for differentiation and the overall success of the drug.
This aggregate rating is based on analysts' research of NeuroBo Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MTVA Analyst Forecast & Price Prediction
Start investing in MTVA
Order type
Buy in
Order amount
Est. shares
0 shares